This site is intended for healthcare professionals
Blue test tubes arranged in a line, disappearing into the background
  • Home
  • /
  • News
  • /
  • 2012
  • /
  • 10
  • /
  • Inlyta (Pfizer) not superior to Nexavar in Renal C...
Drug news

Inlyta (Pfizer) not superior to Nexavar in Renal Cell Carcinoma trial

Read time: 1 mins
Last updated:18th Oct 2012
Published:18th Oct 2012
Source: Pharmawand
"

A Phase III study AGILE 1051, of Inlyta (axitinib) from Pfizer, did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival (PFS), versus Nexavar (sorafenib), in treatment-na�ve patients with advanced Renal Cell Carcinoma (RCC).

A preliminary review of the data showed that overall the median PFS for Inlyta exceeded the median PFS for sorafenib, but did not meet statistical significance. In a pre-specified subgroup of patients classified as good Performance Status (ECOG PS 0) meaning symptomatic but ambulatory, the median PFS for Inlyta exceeded the median PFS for sorafenib. In another pre-specified subgroup of patients classified as intermediate Performance Status (ECOG PS 1) meaning asymptomatic, there was no difference between Inlyta and sorafenib.

How do you prefer to access medical updates and information?

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.